Chronic T-Cell Leukemia (CTCL) Overview

Save information for later
Sign Up

Learn About Chronic T-Cell Leukemia (CTCL)

View Main Condition: Leukemia

What is the definition of Chronic T-Cell Leukemia (CTCL)?
Chronic T-cell leukemia is a type of chronic lymphocytic leukemia (CLL), or cancer of the blood and bone marrow that mainly affects adults. In chronic T-cell leukemia, there is an overproduction of T lymphocytes, which are white blood cells that fight infection. Chronic T-cell leukemia has four subtypes: 1) large granular lymphocytic leukemia (LGLL), which is slow-growing; 2) T-cell prolymphocytic leukemia (T-PLL), which is aggressive, or fast-growing; 3) adult T-cell leukemia/lymphoma (ATLL); and 4) Sezary syndrome, which is a type of T-cell lymphoma that only occurs on the skin.
What are the symptoms of Chronic T-Cell Leukemia (CTCL)?
Individuals with early chronic T-cell leukemia may not have any symptoms. Symptoms of intermediate and advanced stage chronic T-cell leukemia depend on the type and may include painless, enlarged lymph nodes; fatigue; fever; pain in the upper left region of the abdomen; enlarged spleen; easy bruising or bleeding; pinpoint, dark red spots under the skin (petechiae); rash; frequent urination and/or constipation; night sweats; weight loss; abdominal pain or fullness; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic T-Cell Leukemia (CTCL)?
Treatment for chronic T-cell leukemia depends on the type and stage. Early stage chronic T-cell leukemia may not need treatment and may involve watchful waiting. Treatments for intermediate and advanced stages chronic T-cell leukemia may include targeted therapy, chemotherapy, radiation therapy, immunotherapy, splenectomy, and bone marrow or peripheral stem cell transplant.
Who are the top Chronic T-Cell Leukemia (CTCL) Local Doctors?
Robert S. Negrin
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Robert S. Negrin
Hematology | Hematology Oncology | Transplant Surgery
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Robert S. Negrin
Hematology | Hematology Oncology | Transplant Surgery

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (29.9 mi)
650-723-4000
Experience:
41+ years
Languages Spoken:
English
Offers Telehealth

Robert Negrin is a Hematologist and a Hematologist Oncology provider in Stanford, California. Dr. Negrin has been practicing medicine for over 41 years and is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Transplant.

Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Ricardo Guerra
Dermatology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Ricardo Guerra
Dermatology

Permanente Medical Group Inc

320 Lennon Ln, 
Walnut Creek, CA 
 (5.4 mi)
Languages Spoken:
English

Ricardo Guerra is a Dermatologist in Walnut Creek, California. Dr. Guerra and is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Chromoblastomycosis, Epidermodysplasia Verruciformis, Chronic T-Cell Leukemia (CTCL), and Perniosis.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Youn H. Kim
Dermatology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Youn H. Kim
Dermatology

Lymphoma Program

875 Blake Wilbur Drive, 
Palo Alto, CA 
 (29.7 mi)
650-498-6000
Languages Spoken:
English
Offers Telehealth

Youn Kim is a Dermatologist in Palo Alto, California. Dr. Kim and is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Sezary Syndrome.

View All Doctors
What are the latest Chronic T-Cell Leukemia (CTCL) Clinical Trials?
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Who is this study for: Patients with Lymphomas
Enrollment Status: Recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Duvelisib
Study Phase: Phase 1

Summary: This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Registry of the German CLL Study Group Long Term Follow-up of Patients with CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation
Registry of the German CLL Study Group Long Term Follow-up of Patients with CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation
Enrollment Status: Recruiting
Publish Date: December 30, 2024

Summary: Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation

View All Clinical Trials